Shanda H. Blackmon was named director of the Lung Institute at Baylor Medicine.
Something felt wrong during one of Morhaf Al Achkar’s regular runs on the treadmill in late 2016. He started gasping for breath.
Shanda Blackmon named director of Baylor’s Lung Institute
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
In a new online exhibition, The University of Alabama Center for the Study of Tobacco and Society examines tobacco in the tabloids.
The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.
FDA approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test.
The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
In the phase III ADRIATIC trial, Imfinzi (durvalumab) showed a statistically significant and clinically meaningful improvement in overall survival and progression-free survival for patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy, compared to placebo after cCRT.
